NO962188D0 - Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav - Google Patents

Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav

Info

Publication number
NO962188D0
NO962188D0 NO962188A NO962188A NO962188D0 NO 962188 D0 NO962188 D0 NO 962188D0 NO 962188 A NO962188 A NO 962188A NO 962188 A NO962188 A NO 962188A NO 962188 D0 NO962188 D0 NO 962188D0
Authority
NO
Norway
Prior art keywords
proteins
methods
dna encoding
apoptosis modulating
novel apoptosis
Prior art date
Application number
NO962188A
Other languages
English (en)
Other versions
NO962188L (no
Inventor
Michael C Kiefer
Philip J Barr
Original Assignee
Lxr Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lxr Biotechnology Inc filed Critical Lxr Biotechnology Inc
Publication of NO962188D0 publication Critical patent/NO962188D0/no
Publication of NO962188L publication Critical patent/NO962188L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
NO962188A 1993-11-30 1996-05-29 Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav NO962188L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16006793A 1993-11-30 1993-11-30
US32015794A 1994-10-07 1994-10-07
PCT/US1994/013930 WO1995015084A1 (en) 1993-11-30 1994-11-30 Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
NO962188D0 true NO962188D0 (no) 1996-05-29
NO962188L NO962188L (no) 1996-07-23

Family

ID=26856568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962188A NO962188L (no) 1993-11-30 1996-05-29 Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav

Country Status (14)

Country Link
US (7) US6015687A (no)
EP (1) EP0731636B1 (no)
JP (4) JP4129055B2 (no)
CN (1) CN1139871A (no)
AT (1) ATE315643T1 (no)
AU (1) AU688839B2 (no)
CA (1) CA2177827C (no)
DE (1) DE69434614T2 (no)
ES (1) ES2256843T3 (no)
FI (1) FI962247A (no)
HU (1) HUT74276A (no)
NO (1) NO962188L (no)
NZ (1) NZ277946A (no)
WO (1) WO1995015084A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2256843T3 (es) * 1993-11-30 2006-07-16 Tanox, Inc. Proteinas con que modulan la apoptosis, adn codante para estas proteinas, y su modo de utilizacion.
US5998131A (en) * 1994-10-07 1999-12-07 Lxr Biotechnology, Inc. Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
JPH1189573A (ja) * 1994-10-14 1999-04-06 Yutaka Shindo アポトーシス関与遺伝子
WO1996033416A1 (en) * 1995-04-20 1996-10-24 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apoptosis-modulating proteins
CA2289122C (en) * 1997-02-18 2009-04-21 Lxr Biotechnology Inc. Bak promoter expression system
US6441135B1 (en) * 1997-03-20 2002-08-27 Tanox, Inc. Bak binding protein, DNA encoding the protein, and methods of use thereof
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6218144B1 (en) * 1997-06-30 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Costal2 genes and their uses
US6641998B2 (en) * 1997-10-10 2003-11-04 Stratagene Methods and kits to enrich for desired nucleic acid sequences
ATE382148T1 (de) * 1998-09-24 2008-01-15 Promega Corp Antikörper für apoptosemarker und anwendungsverfahren
AU760466B2 (en) 1999-02-26 2003-05-15 Johns Hopkins University, The A novel inhibitor of programmed cell death
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20010053769A1 (en) 2000-01-21 2001-12-20 Christiane Ferran Use of pro-apoptotic factors in treatment of atherosclerosis
EP1349929A2 (de) * 2000-07-14 2003-10-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Apoptose-induzierende dna-sequenzen
CA2439532A1 (en) * 2001-03-02 2002-09-26 Mds Proteomics Inc. Methods and reagents for regulating apoptosis
EP1253200A1 (en) * 2001-04-25 2002-10-30 Société des Produits Nestlé S.A. Cocoa polypeptides and their use in the production of cocoa and chocolate flavour
PT1432450E (pt) * 2001-10-03 2006-05-31 Bioniche Life Sciences Inc Trietilenoglicol-colesteril-oligonucleotidos terapeuticamente uteis
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
AU2003298014A1 (en) * 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004072225A2 (en) * 2003-02-12 2004-08-26 Ramot At Tel Aviv University Ltd. Transgenic fungi expressing bcl-2 and methods of using bcl-2 or portions thereof for improving biomass production, survival, longevity, stress resistance and pathogenicity of fungi
EP1644038A2 (en) * 2003-06-23 2006-04-12 A & G Pharmaceuticals, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
EP1660010B1 (en) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
PT1978993T (pt) * 2005-10-31 2017-03-17 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro com base em recetores fzd humanos
WO2011056886A2 (en) * 2009-11-03 2011-05-12 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
EP2418286A1 (en) * 2010-08-10 2012-02-15 QIAGEN GmbH Improved method for isothermal amplification of nucleic acids
US20130166458A1 (en) * 2011-12-22 2013-06-27 Embraer S.A. System and method for remote and automatic assessment of structural damage and repair
US20230392166A1 (en) * 2020-10-21 2023-12-07 Wisconsin Alumni Research Foundation Anti-apoptotic vector and method of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2515992A (en) * 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5395767A (en) * 1992-06-22 1995-03-07 Regents Of The University Of California Gene for ataxia-telangiectasia complementation group D (ATDC)
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
JPH08511690A (ja) * 1993-06-24 1996-12-10 ザ・ジェネラル・ホスピタル・コーポレーション プログラムされた細胞死遺伝子及びタンパク質
WO1995005738A1 (en) * 1993-08-20 1995-03-02 Massachusetts Institute Of Technology Anticancer agents and apoptosis
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
ES2256843T3 (es) * 1993-11-30 2006-07-16 Tanox, Inc. Proteinas con que modulan la apoptosis, adn codante para estas proteinas, y su modo de utilizacion.
US5672686A (en) * 1994-08-09 1997-09-30 Immunogen, Inc. Bcl-Y - specific antibodies
WO1996033416A1 (en) * 1995-04-20 1996-10-24 Lxr Biotechnology Inc. Methods of screening for therapeutic agents using novel apoptosis-modulating proteins
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7

Also Published As

Publication number Publication date
HU9601448D0 (en) 1996-07-29
US7754418B2 (en) 2010-07-13
EP0731636A4 (en) 1998-04-15
JPH09509567A (ja) 1997-09-30
AU1335195A (en) 1995-06-19
CN1139871A (zh) 1997-01-08
FI962247A (fi) 1996-07-22
JP2006061159A (ja) 2006-03-09
HUT74276A (en) 1996-11-28
US5770443A (en) 1998-06-23
CA2177827A1 (en) 1995-06-08
US6586395B1 (en) 2003-07-01
EP0731636A1 (en) 1996-09-18
DE69434614T2 (de) 2006-10-05
EP0731636B1 (en) 2006-01-11
ATE315643T1 (de) 2006-02-15
NZ277946A (en) 1998-03-25
US6015687A (en) 2000-01-18
JP2009189377A (ja) 2009-08-27
US6903195B1 (en) 2005-06-07
FI962247A0 (fi) 1996-05-29
JP2007252391A (ja) 2007-10-04
US20050164284A1 (en) 2005-07-28
US20070117748A1 (en) 2007-05-24
NO962188L (no) 1996-07-23
WO1995015084A1 (en) 1995-06-08
ES2256843T3 (es) 2006-07-16
AU688839B2 (en) 1998-03-19
CA2177827C (en) 2007-08-28
JP4129055B2 (ja) 2008-07-30
US7108989B2 (en) 2006-09-19
DE69434614D1 (de) 2006-04-06
US20030008837A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
NO962188D0 (no) Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav
DK0652960T3 (da) Cyklisk GMP-bindende, cyklisk GMP-specifikke phosphodiesterasematerialer og fremgangsmåder
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
ATE192496T1 (de) Ubiquitinspezifische proteasen
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
FI961886A (fi) Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
DK372086D0 (da) Fremgangsmaade til rekombinant-dna-syntese af en serinproteaseinhibitor og dna-sekvenser, som er nyttige derved
DK0981631T3 (da) Polypeptider, som har aminopeptidase-aktivitet, og nukleinsyrer, som koder for samme
HUP9904414A2 (hu) A neuritin neurogén
DK0719328T3 (da) Genet GRB 3-3, varianter deraf og anvendelse deraf
NO972313L (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
DK130290D0 (da) Lymfokiner, dna-sekvenser, som koder for disse lymfokiner og farmaceutiske midler indeholdende disse lymfokiner
HUP0203080A2 (hu) A PRV-1 gén és felhasználása
ITRM950434A0 (it) Polipeptide per la riparazione di informazione genetica, sequenza nucleotidica che codifica per esso e procedimento per la sua preparazione.
ATE369381T1 (de) NUKLEARES PROTEIN ßSHOCAß - EINE KOMPONENTE DES WNT SIGNALTRANSDUKTIONSWEGES
ATE104344T1 (de) Gereinigte ubiquitin-hydrolase, diese kodierende dns-sequenzen und ihre verwendung zur gewinnung von polypeptiden.
BR9607577A (pt) Método para inibir catepsina k